Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma.
Nassar KM, Yang X, Baker A, Gopalam R, Arnold WC, Adeniran TT, Hernandez Fernandez MH, Mahajan M, Lai Z, Chen Y, Sareddy GR, Viswanadhapalli S, Sun LZ, Vadlamudi RK, Pratap UP. Nassar KM, et al. Among authors: lai z. Cancer Res Commun. 2024 Oct 1;4(10):2610-2620. doi: 10.1158/2767-9764.CRC-24-0173. Cancer Res Commun. 2024. PMID: 39258975 Free PMC article.
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z, Liu J, Ebrahimi B, Pratap UP, He Y, Altwegg KA, Tang W, Li X, Lai Z, Chen Y, Shen L, Sareddy GR, Viswanadhapalli S, Tekmal RR, Rao MK, Vadlamudi RK. Liu Z, et al. Among authors: lai z. Breast Cancer Res. 2022 Apr 8;24(1):26. doi: 10.1186/s13058-022-01520-4. Breast Cancer Res. 2022. PMID: 35395812 Free PMC article.
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK. Altwegg KA, et al. Among authors: lai z. Cancer Res. 2022 Oct 17;82(20):3830-3844. doi: 10.1158/0008-5472.CAN-22-0698. Cancer Res. 2022. PMID: 35950923 Free PMC article.
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M, Venkata PP, Viswanadhapalli S, Palacios B, Alejo S, Chen Y, He Y, Pratap UP, Liu J, Zou Y, Lai Z, Suzuki T, Brenner AJ, Tekmal RR, Vadlamudi RK, Sareddy GR. Zhou M, et al. Among authors: lai z. Breast Cancer Res Treat. 2021 Jan;185(2):343-357. doi: 10.1007/s10549-020-05963-1. Epub 2020 Oct 14. Breast Cancer Res Treat. 2021. PMID: 33057995
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP, Chen Y, Alejo S, He Y, Palacios BE, Loeffel I, Liu J, Pratap UP, Gray G, Achuthan Pillai SM, Zou Y, Lai Z, Suzuki T, Viswanadhapalli S, Palakurthi S, Tekmal RR, Vadlamudi RK, Kost E, Sareddy GR. Venkata PP, et al. Among authors: lai z. Cancer Lett. 2022 Jan 1;524:219-231. doi: 10.1016/j.canlet.2021.10.019. Epub 2021 Oct 18. Cancer Lett. 2022. PMID: 34673129 Free PMC article.
Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Pratap UP, Tidwell M, Balinda HU, Clanton NA, Yang X, Viswanadhapalli S, Sareddy GR, Liang D, Xie H, Chen Y, Lai Z, Tekmal RR, McHardy SF, Brenner AJ, Vadlamudi RK. Pratap UP, et al. Among authors: lai z. Mol Cancer Ther. 2023 Nov 1;22(11):1248-1260. doi: 10.1158/1535-7163.MCT-23-0031. Mol Cancer Ther. 2023. PMID: 37493258 Free PMC article.
2,201 results